期刊文献+

RP-HPLC法测定犬血浆中奈诺沙星浓度

Determination of nemonoxacin in dog plasma by RP-HPLC
下载PDF
导出
摘要 目的采用HPLC法测定比格犬血浆中喹诺酮类药物奈诺沙星的浓度。方法以莫西沙星作为内标,血浆样品经二氯甲烷萃取后,采用HPLC法进行测定,色谱柱为Welchrom DOS-C18 (200mm×6mm,5μm),流动相为乙腈-水(含0.2%三乙胺,磷酸调pH2.8)(22:78),检测波长292nm,流速1mL/min,柱温40℃。结果血浆中奈诺沙星的线性范围为0.1~12.0μg/mL(r=0.9996),平均方法回收率为101.25%,日内RSD〈8.0%,日间RSD〈8.5%。结论所用方法的专属性强、准确、灵敏、快速简便,适用于测定血浆中奈诺沙星的浓度。 Objective To establish an HPLC method for determination of nemonoxacin in beagles plasma. Methods Moxifloxacin was used as internal standard, the plasma samples were pretreated by dichloridimethane, and then analyzed by HPLC. The HPLC was performed on a Welchrom DOS-C18 column (200mm×4.6mm, 5μm) with UV detection at 292nm, using phosphoric acid solution (containing 0.2% triethylamine, adjusted to pH2.8 with phosphoric acid ) and acetonitile (78:22) as mobile phase at 1.0mL/min flow rate, And the column temperature was 40~C. Results The concentration of nemonoxacin was in good linearity in the range of 0.1-12.0pg/mL (r=0.9996). The average recovery rate was 101.25%.The within-day and between-day RSD were less than 8.5%. Conclusion The method was simple, sensitive and accurate,. It can be used for determination ofnemonoxacin in plasm sample.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2016年第9期671-674,共4页 Chinese Journal of Antibiotics
基金 抗生素研究与再评价四川省重点实验室开放课题(No.ARRLKF14-10)
关键词 反向高效液相色谱法 喹诺酮类 奈诺沙星 血药浓度 RP-HPLC Quinolones Nemonoxacin Blood concentration
  • 相关文献

参考文献5

二级参考文献32

  • 1Arjona A. Nemonoxacin[J]. Drugs of the Future, 2009, 34 (3) : 196-203.
  • 2Chen YH, Liu CY, Lu JJ, et al. Invitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phetlotypes in Taiwan[J]. J Antimicrob Chemother, 2009, 64(6)1226-1229.
  • 3Adam HJ, Laing NM, King CR, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2, 440 clinical isolates [J]. Antimicrob Agents Chemother, 2009, 53(11): 4915-4920.
  • 4Lin L, Chang LW, Tsai CY, et al. Dose escalation study of the safety, tolerahility, and pharmaeokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinoione, in healthy volunteers[J]. Antimicrob Agents Chemother, 2010, 54(1): 405-410.
  • 5Chung DT, Tsai CY, Chen SJ, et al. Multiple-dose safety, tolerability, and pharmaeokinetics of oral nemonoxaein (TG- 873870) in healthy volunteers[J]. Antimicrob Agents Chemother, 2010, 54(1): 411-417.
  • 6张旭宏.太景生技首创完成两岸奈诺沙星NDA申请.
  • 7宝洁公司.用于制备喹诺酮中间体的偶联方法[P]中国,1010457242007.
  • 8Chava S,Dammalapati VLN,Gorantla SR. An improved process for the preparation of moxifloxacin hydrochloride[P].WO,2005012285,2005.
  • 9Arjona A, Castanet R, Bolos J. Nemonoxacin, Drugs of the future, 2009, 34(3) : 196-203.
  • 10Adam HJ, Laing NM, King CR, et al. In vitro activity of nemonoxacin , a novel nonfluorinated quinolone, against 2440 clinical isolates[J]. Antimicrob Agents Chemother, 2009,53 ( 11 ) :4915-4920.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部